Study Gauges 340B Orphan Drug Discount Restriction’s Effect

by Admin | March 19, 2012 2:47 pm

March 19, 2012—Critical access hospitals (CAHs) are spending significantly more on orphan drugs than they otherwise would if they could buy the medicines at 340B discounted prices, a new study suggests.

The research, published in the University of Minnesota College of Pharmacy’s Innovations in Pharmacy quarterly[1], found that a group of 18 CAHs in Minnesota and Wisconsin spent a combined $9.9 million on 111 drugs with orphan designations in 2010, paying wholesale acquisition cost (WAC) or prices negotiated by their group purchasing organization. 

---

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[2].    Already registered? Click here to login[3]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Source URL: https://340binformed.org/2012/03/study-gauges-340b-orphan-drug-discount-restrictions-effect/

---